|
1
|
Wiley SR, Schooley K, Smolak PJ, et al:
Identification and characterization of a new member of the TNF
family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ashkenazi A, Pai RC, Fong S, et al: Safety
and antitumor activity of recombinant soluble Apo2 ligand. J Clin
Invest. 104:155–162. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keane MM, Ettenberg SA, Nau MM, Russell EK
and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in
breast cell lines. Cancer Res. 59:734–741. 1999.PubMed/NCBI
|
|
4
|
Schow P, Hooley J, Sherwood S, et al:
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL
versions. Nat Med. 7:383–385. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pan G, O’Rourke K, Chinnaiyan AM, et al:
The receptor for the cytotoxic ligand TRAIL. Science. 276:111–113.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pan G, Ni J, Wei YF, Yu G, Gentz R and
Dixit VM: An antagonist decoy receptor and a death
domain-containing receptor for TRAIL. Science. 277:815–818. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang S and El-Deiry WS: TRAIL and
apoptosis induction by TNF-family death receptors. Oncogene.
22:8628–8633. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelley RF, Totpal K, Lindstrom SH, et al:
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor
necrosis factor-related apoptosis inducing ligand reveal a greater
contribution of death receptor (DR) 5 than DR4 to apoptosis
signaling. J Biol Chem. 280:2205–2212. 2005. View Article : Google Scholar
|
|
9
|
Ichikawa K, Liu W, Zhao L, et al:
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody
without hepatocyte cytotoxicity. Nat Med. 7:954–960. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koornstra JJ, Kleibeuker JH, van Geelen
CM, et al: Expression of TRAIL (TNF-related apoptosis-inducing
ligand) and its receptors in normal colonic mucosa, adenomas, and
carcinomas. J Pathol. 200:327–335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Herbst RS, Eckhardt SG, Kurzrock R, et al:
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a
dual proapoptotic receptor agonist, in patients with advanced
cancer. J Clin Oncol. 28:2839–2846. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tontonoz P, Hu E, Graves RA, Budavari AI
and Spiegelman BM: mPPAR gamma 2: tissue-specific regulator of an
adipocyte enhancer. Genes Dev. 8:1224–1234. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tontonoz P, Hu E and Spiegelman BM:
Stimulation of adipogenesis in fibroblasts by PPARγ2, a
lipid-activated transcription factor. Cell. 79:1147–1156. 1994.
|
|
14
|
Chawla A, Schwarz EJ, Dimaculangan DD and
Lazar MA: Peroxisome proliferator-activated receptor (PPAR) gamma:
adipose-predominant expression and induction early in adipocyte
differentiation. Endocrinology. 135:798–800. 1994.
|
|
15
|
Fujiwara T, Yoshioka S, Yoshioka T,
Ushiyama I and Horikoshi H: Characterization of new oral
antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker
fatty rats. Diabetes. 37:1549–1558. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lehmann JM, Moore LB, Smith-Oliver TA,
Wilkison WO, Willson TM and Kliewer SA: An antidiabetic
thiazolidinedione is a high affinity ligand for peroxisome
proliferator-activated receptor γ (PPARγ). J Biol Chem.
270:12953–12956. 1995.
|
|
17
|
Kubota T, Koshizuka K, Williamson EA, et
al: Ligand for peroxisome proliferator-activated receptor γ
(troglitazone) has potent antitumor effect against human prostate
cancer both in vitro and in vivo. Cancer Res. 58:3344–3352.
1998.
|
|
18
|
Grommes C, Landreth GE and Heneka MT:
Antineoplastic effects of peroxisome proliferator-activated
receptor γ agonists. Lancet Oncol. 5:419–429. 2004.
|
|
19
|
Kulke MH, Demetri GD, Sharpless NE, et al:
A phase II study of troglitazone, an activator of the PPARγ
receptor, in patients with chemotherapy-resistant metastatic
colorectal cancer. Cancer J. 8:395–399. 2002.PubMed/NCBI
|
|
20
|
Burstein HJ, Demetri GD, Mueller E, Sarraf
P, Spiegelman BM and Winer EP: Use of the peroxisome
proliferator-activated receptor (PPAR) γ ligand troglitazone as
treatment for refractory breast cancer: a phase II study. Breast
Cancer Res Treat. 79:391–397. 2003.
|
|
21
|
Xu C, Bailly-Maitre B and Reed JC:
Endoplasmic reticulum stress: cell life and death decisions. J Clin
Invest. 115:2656–2664. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oyadomari S and Mori M: Roles of
CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ.
11:381–389. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maniratanachote R, Minami K, Katoh M,
Nakajima M and Yokoi T: Chaperone proteins involved in
troglitazone-induced toxicity in human hepatoma cell lines. Toxicol
Sci. 83:293–302. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Satoh T, Toyoda M, Hoshino H, et al:
Activation of peroxisome proliferator-activated receptor-γ
stimulates the growth arrest and DNA-damage inducible 153 gene in
non-small cell lung carcinoma cells. Oncogene. 21:2171–2180.
2002.
|
|
25
|
Koyama M, Matsuzaki Y, Yogosawa S, Hitomi
T, Kawanaka M and Sakai T: ZD1839 induces p15INK4b and
causes G1 arrest by inhibiting the mitogen-activated
protein kinase/extracellular signal-regulated kinase pathway. Mol
Cancer Ther. 6:1579–1587. 2007.PubMed/NCBI
|
|
26
|
Koyama M, Izutani Y, Goda AE, et al:
Histone deacetylase inhibitors and
15-deoxy-Δ12,14-prostaglandin J2
synergistically induce apoptosis. Clin Cancer Res. 16:2320–2332.
2010.
|
|
27
|
Elstner E, Müller C, Koshizuka K, et al:
Ligands for peroxisome proliferator-activated receptor γ and
retinoic acid receptor inhibit growth and induce apoptosis of human
breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci
USA. 95:8806–8811. 1998.
|
|
28
|
Lu M, Kwan T, Yu C, et al: Peroxisome
proliferator-activated receptor γ agonists promote TRAIL-induced
apoptosis by reducing survivin levels via cyclin D3 repression and
cell cycle arrest. J Biol Chem. 280:6742–6751. 2005.
|
|
29
|
Ubeda M and Habener JF: CHOP gene
expression in response to endoplasmic-reticular stress requires NFY
interaction with different domains of a conserved DNA-binding
element. Nucleic Acids Res. 28:4987–4997. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Walczak H, Degli-Esposti MA, Johnson RS,
et al: Cloning and characterization of TRAIL-R3, a novel member of
the emerging TRAIL receptor family. J Exp Med. 186:1165–1170. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Degli-Esposti MA, Dougall WC, Smolak PJ,
Waugh JY, Smith CA and Goodwin RG: The novel receptor TRAIL-R4
induces NF-κB and protects against TRAIL-mediated apoptosis, yet
retains an incomplete death domain. Immunity. 7:813–820. 1997.
|
|
32
|
Emery JG, McDonnell P, Burke MB, et al:
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J
Biol Chem. 273:14363–14367. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mitsiades N, Poulaki V, Mitsiades C and
Tsokos M: Ewing’s sarcoma family tumors are sensitive to tumor
necrosis factor-related apoptosis-inducing ligand and express death
receptor 4 and death receptor 5. Cancer Res. 61:2704–2712.
2001.
|
|
34
|
Jang YJ, Park KS, Chung HY and Kim HI:
Analysis of the phenotypes of Jurkat clones with different
TRAIL-sensitivities. Cancer Lett. 194:107–117. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hellwig CT and Rehm M: TRAIL signaling and
synergy mechanisms used in TRAIL-based combination therapies. Mol
Cancer Ther. 11:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yee L, Fanale M, Dimick K, et al: A Phase
IB safety and pharmacokinetic (PK) study of recombinant human
Apo2L/TRAIL in combination with rituximab in patients with
low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 25:S4602007.
|
|
37
|
Soria JC, Smit E, Khayat D, et al: Phase
1b study of dulanermin (recombinant human Apo2L/TRAIL) in
combination with paclitaxel, carboplatin, and bevacizumab in
patients with advanced non-squamous non-small-cell lung cancer. J
Clin Oncol. 28:1527–1533. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Soria JC, Márk Z, Zatloukal P, et al:
Randomized phase II study of dulanermin in combination with
paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell
lung cancer. J Clin Oncol. 29:4442–4451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yoshida T, Shiraishi T, Nakata S, et al:
Proteasome inhibitor MG132 induces death receptor 5 through
CCAAT/enhancer-binding protein homologous protein. Cancer Res.
65:5662–5667. 2005. View Article : Google Scholar
|
|
40
|
Shiraishi T, Yoshida T, Nakata S, et al:
Tunicamycin enhances tumor necrosis factor-related
apoptosis-inducing ligand-induced apoptosis in human prostate
cancer cells. Cancer Res. 65:6364–6370. 2005. View Article : Google Scholar
|
|
41
|
Gitlin N, Julie NL, Spurr CL, Lim KN and
Juarbe HM: Two cases of severe clinical and histologic
hepatotoxicity associated with troglitazone. Ann Intern Med.
129:36–38. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Scheen AJ: Thiazolidinediones and liver
toxicity. Diabetes Metab. 27:305–313. 2001.PubMed/NCBI
|
